Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2.

Authors

Drishya Kurup, Thomas Jefferson UniversityFollow
Christoph Wirblich, Thomas Jefferson UniversityFollow
Holly Ramage, Thomas Jefferson UniversityFollow
Matthias J Schnell, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

10-2020

Comments

This is the final published version of the article from NPJ Vaccines, 2020, Oct 16;5:98.

The final version of the article can also be found at https://doi.org/10.1038/s41541-020-00248-6.

Copyright. The Authors.

Abstract

The recently emerged coronavirus SARS-CoV-2, the causative agent of COVID-19, is rapidly spreading in the world. The exponentially expanding threat of SARS-CoV-2 to global health highlights the urgent need for a vaccine. Herein we show the rapid development of a novel, highly efficient, and safe COVID-19 vaccine using a rabies virus-based vector that has proven to be an efficient vaccine against several emerging infectious diseases. This study reports that both a live and an inactivated rabies virus containing the SARS-CoV-2 spike S1 protein induces potent virus-neutralizing antibodies at much higher levels than seen in the sera of convalescent patients. In summary, the results provided here warrant further development of this safe and established vaccine platform against COVID-19.

Recommended Citation

Kurup, Drishya; Wirblich, Christoph; Ramage, Holly; and Schnell, Matthias J, "Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2." (2020). Department of Microbiology and Immunology Faculty Papers. Paper 119.
https://jdc.jefferson.edu/mifp/119

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

33088593